Molecular Oncology
Volume 3, Issue 5 , Pages 425-438 , December 2009

Characterizing DNA methylation patterns in pancreatic cancer genome

  • Aik Choon Tan

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Antonio Jimeno

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Steven H. Lin

      Affiliations

    • Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Jenna Wheelhouse

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Fonda Chan

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Anna Solomon

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • N.V. Rajeshkumar

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Belen Rubio-Viqueira

      Affiliations

    • Centro Integral Oncologico “Clara Campal”, Calle Oña, 10, 28050 Madrid, Spain
    • ,
  • Manuel Hidalgo

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • Centro Integral Oncologico “Clara Campal”, Calle Oña, 10, 28050 Madrid, Spain
    • Corresponding Author InformationCorrespondence to: Manuel Hidalgo, MD, PhD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St., Room 489, Baltimore, MD 21231, USA. Tel.: +1 410 5029746; fax: +1 410 6149006.

Received 3 February 2009 ,Revised 6 March 2009 ,Accepted 9 March 2009.

References 

  1. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Research. 2006;16:383–393
  2. Chen J, Rocken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, et al. The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Letters. 2006;233:328–337
  3. Cui H, Onyango P, Brandenburg S, Wu Y, Hsieh CL, Feinberg AP. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Research. 2002;62:6442–6446
  4. de Hoon MJL, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. 2004;20:1453–1454
  5. De Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Molecular and Cellular Biology. 2004;24:4781–4790
  6. Ebert MPA, Hernberg S, Fei G, Sokolowski A, Schulz HU, Lippert H, et al. Induction and expression of cyclin D3 in human pancreatic cancer. Journal of Cancer Research and Clinical Oncology. 2001;127:449–454
  7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics. 2007;8:286–298
  8. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Research. 2001;61:3225–3229
  9. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. The New England Journal of Medicine. 2000;343:1350–1354
  10. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nature Reviews Genetics. 2006;7:21–33
  11. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Research. 1997;57:1634–1637
  12. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–537
  13. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Research. 2002;62:2890–2896
  14. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine. 2003;349:2042–2054
  15. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, Van Heek NT, Rosty C, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. American Journal of Pathology. 2003;162:1151–1162
  16. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van Heek T, Ashfaq R, Meyer R, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. American Journal of Pathology. 2002;160:1239–1249
  17. Jacquemin P, Lannoy VJ, Rousseau GG, Lemaigre FP. OC-2, a novel mammalian member of the ONECUT class of homeodomain transcription factors whose function in liver partially overlaps with that of hepatocyte nuclear factor-6. Journal of Biological Chemistry. 1999;274:2665–2671
  18. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. 2007;57:43–66
  19. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Molecular Cancer Therapeutics. 2006;5:787–796
  20. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics. 2002;3:415–428
  21. Kuhlmann KFD, van Till JWO, Boermeester MA, de Reuver PR, Tzvetanova ID, Offerhaus GJA, et al. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiology, Biomarkers & Prevention. 2007;16:886–891
  22. Laird PW. The power and the promise of DNA methylation markers. Nature Reviews Cancer. 2003;3:253–266
  23. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Research. 2003;63:2649–2657
  24. Lowe AW, Olsen M, Hao Y, Lee SP, Taek Lee K, Chen X, et al. Gene expression patterns in pancreatic tumors, cells and tissues. PLoS ONE. 2007;2:e323
  25. Matsubayashi H, Sato N, Fukushima N, Yeo CJ, Walter KM, Brune K, et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clinical Cancer Research. 2003;9:1446–1452
  26. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clinical Cancer Research. 2005;11:8321–8325
  27. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clinical Cancer Research. 2006;12:4652–4661
  28. Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Research. 2002;62:819–826
  29. Saldanha AJ. Java Treeview – extensible visualization of microarray data. Bioinformatics. 2004;20:3246–3248
  30. Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Research. 2003;63:4158–4166
  31. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Research. 2003;63:8606–8613
  32. Satoh Y, Nakagawachi T, Nakadate H, Kaneko Y, Masaki Z, Mukai T, et al. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor. The Journal of Biochemistry. 2003;133:303–308
  33. Scholz C, Nimmrich I, Burger M, Becker E, Dörken B, Ludwig WD, et al. Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis. Annals of Hematology. 2005;84:236–244
  34. Shen L, Kondo Y, Ahmed S, Boumber Y, Konishi K, Guo Y, et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Research. 2007;67:11335–11343
  35. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:5116–5121
  36. Wood LD, Calhoun ES, Silliman N, Ptak J, Szabo S, Powell SM, et al. Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Human Mutation. 2006;27:1060–1061
  37. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. Journal of Clinical Oncology. 2006;24:1761–1769
  38. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Research. 2004;64:1975–1986

PII: S1574-7891(09)00032-5

doi: 10.1016/j.molonc.2009.03.004

Molecular Oncology
Volume 3, Issue 5 , Pages 425-438 , December 2009

Article Tools

* Image Usage & Resolution